Nipro Corporation
Stock Price Chart
2026/03/02 UpdatedPrice Trend
2026/03/02 UpdatedPrice & Trading Details
2026/03/02 UpdatedPRICE
TRADING
Analyst Recommendations 5 analysts
Updated 2026/03/01Shareholder Composition
Updated 2026/03/01Major Holders
Updated 2026/03/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
American Century ETF Trust-Avantis International Small Cap Value ETF
|
3.4M | +2.83% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
2.2M | +6.96% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
1.4M | +12.59% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
981.8K | 0.00% | |
|
DFA INVESTMENT DIMENSIONS GROUP INC-DFA Intl Small Cap Value PORT.
|
805.0K | 0.00% | |
|
DFA INVESTMENT TRUST CO-The Japanese Small Company Series
|
640.4K | -15.79% |
Dividend History
Updated 2026/03/01| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥23 | -14.8% |
| 2024 | ¥27 | +45.9% |
| 2023 | ¥19 | -28.8% |
| 2022 | ¥26 | -16.1% |
| 2021 | ¥31 | - |
Financial Performance
2026/03/01 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥494,789M | ¥545,199M | ¥586,785M | ¥644,586M |
| Gross Profit | ¥149,269M | ¥163,449M | ¥171,320M | ¥190,883M |
| Operating Income | ¥23,883M | ¥17,729M | ¥22,335M | ¥26,598M |
| Pretax Income | ¥27,378M | ¥21,278M | ¥25,746M | ¥26,931M |
| Net Income | ¥13,455M | ¥4,574M | ¥11,109M | ¥5,113M |
| EPS | ¥77.42 | ¥24.85 | ¥24.85 | ¥27.78 |
| Operating Margin | 4.83% | 3.25% | 3.81% | 4.13% |
| Balance Sheet | ||||
| Total Assets | ¥930,321M | ¥1,027,399M | ¥1,109,821M | ¥1,170,564M |
| Total Equity | ¥185,238M | ¥206,317M | ¥232,664M | ¥252,445M |
| Total Liabilities | ¥745,083M | ¥821,082M | ¥877,157M | ¥918,119M |
| Cash | ¥95,342M | ¥89,678M | ¥99,667M | ¥106,668M |
| Interest-bearing Debt | ¥564,852M | ¥605,931M | ¥635,687M | ¥636,873M |
| Equity Ratio | 19.91% | 20.08% | 20.96% | 21.57% |
| D/E Ratio | 3.05 | 2.94 | 2.73 | 2.52 |
| Cash Flow | ||||
| Operating CF | ¥68,214M | ¥10,395M | ¥72,936M | ¥68,461M |
| Investing CF | -¥78,434M | -¥71,737M | -¥87,075M | -¥71,876M |
| Financing CF | ¥10,297M | ¥43,077M | ¥22,142M | ¥5,376M |
| Free CF | ¥68,214M | ¥10,395M | ¥72,936M | ¥68,461M |
| Efficiency | ||||
| ROE | 7.26% | 2.22% | 4.77% | 2.03% |
| ROA | 1.45% | 0.45% | 1.00% | 0.44% |
Latest IR Information
-
Notice Regarding Establishment of the Nomination and Remuneration Committee
Effective April 1, 2026, Nipro Corporation will establish a 'Nomination and Remuneration Committee' with added authority over director nominations to enhance corporate governance.
Read more -
Notice Regarding Recording of Special Gain (Gain on Step Acquisition)
In the third quarter of the fiscal year ending March 2026, a special gain of JPY 5,169 million was recorded related to additional acquisition of equity interest in G2/Spryte Holdco, LLC.
Read more -
Financial Summary for Q3 FY March 2026 [Japanese GAAP] (Consolidated)
For the third quarter of the fiscal year ending March 2026, consolidated net sales were 487.305 billion yen (1.7% YoY increase), operating income was 26.747 billion yen (20.5% YoY increase), and net income attributable to owners of the parent for...
Read more
Latest News (5 items)
-
Average Analyst Rating: hold
Average Target Price: ¥1,444
Rating Score: 2.60 (Based on 5 analysts)
※1=Strong Buy, 5=Strong Sell
Samsung Bioepis wins approval to sell autoimmune biosimilar in Japan - Yonhap News Agency ↗
Company Information
About
Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses. Its Medical-Related business develops, manufactures, and sells injection and infusion products, artificial organ-related products, functional products, dialysis products, cell cultures, hospital products, diabetic products, and pharmaceuticals comprising generic and kit products; and manufactures medical equipment, including dialysis medical device products; and operates dialysis and training centers. The company's Pharmaceutical-Related business engages in the contract manufacturing of pharmaceutical products with containers for combination products, including injectable kit products consigned by other pharmaceutical companies; and provides injectable, oral drugs products. In addition, its Pharma Packaging business offers pharmaceutical packaging containers and glass tubing, such as molded components for vials, syringes, rubber stoppers, and devices used to administer pharmaceuticals; and glass for thermos bottles, lighting and containers for combination products, glass equipment, as well glass for ampoules. Further, the company serves customers in Japan, the Americas, Europe, and rest of Asia. Nipro Corporation was founded in 1947 and is based in Settsu, Japan.
